Minerva Neurosciences | NERV - Ebitda


Minerva Neurosciences reported $-4.36M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Adma Biologics USD 61.07M 12.52M Mar/2026
ALKERMES USD 80.26M 20.05M Mar/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cipla INR 14.03B 4.48B Jun/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
J&J USD 8.27B 1.08B Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.31B 3.65B Mar/2026
Takeda JPY 150.25B 297.88B Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024